Stock Expert AI
Equity research screen

LLY vs. NVO: Stock Comparison

This page provides a comparative analysis of Eli Lilly (LLY) and Novo Nordisk (NVO). The comparison leverages available stock data and market context to support investment decision-making. This resource offers a balanced perspective on two prominent pharmaceutical companies, without offering investment advice or endorsements.

Quick Answer This page offers a data-driven comparison between Eli Lilly (LLY) and Novo Nordisk (NVO), two leading pharmaceutical companies. The analysis considers their market positions and other relevant financial metrics. This comparison framework allows readers to form an opinion based on available data.
Screens40Average score94.50Updated2026-04-10Prices as ofOct 26, 2026 session

Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures.

MoonshotScore V2 rates eligible US-listed companies from 0 to 100 against their sector peers on five pillars: Business Quality (weight 26), Financial Safety (weight 20), Valuation (weight 18), Growth Durability (weight 16) and Momentum (weight 12). It reads no news-sentiment or analyst data, and it is not a probability of future returns.

20,000+ US companies analyzed

LLY vs. NVO: An Equity Comparison

This analysis examines Eli Lilly and Company (LLY) against Novo Nordisk (NVO) to highlight their respective positions in the pharmaceutical sector. The comparison focuses on factors relevant to assessing potential investment opportunities, aiding readers in forming their own informed opinions.

LLY vs NVO: The Numbers

Side by side on the figures we publish for both companies. Not a ranking and not a recommendation — the same metrics, read off the same source, on the same day.

LLY and NVO on five published metrics — MoonshotScore and P/E from our latest stored data; prices, day change and market cap as of the Oct 26, 2026 trading session (FMP quote). Source: Financial Modeling Prep, Yahoo Finance.
Metric LLYEli LillyNVONovo Nordisk
MoonshotScore 9891
Price $1279.14$39.13
Change (1D) +0.45%+0.20%
Market cap $1.2T$173.0B
P/E ratio ——

A dash means we hold no published figure for that company — not a zero. Full analysis: LLY · NVO.

Key Considerations

When evaluating LLY versus NVO, consider the following points: each company's financial stability, market position, and recent performance. These factors can influence potential investment returns and risk profiles.
“MoonshotScore rates a US-listed stock 0 to 100 using five sector-relative pillars. Higher means stronger numbers across business quality, safety, valuation, growth and momentum. Eligible common stocks and ADRs only; funds, ETFs, warrants, units, SPACs, preferreds, and notes carry none. It is built for education and deeper due diligence, not financial advice.”
— Stock Expert AI published methodology (how MoonshotScore works)

Questions worth resolving before acting on the screen

What are the MoonshotScores of LLY and NVO?

LLY (Eli Lilly) has a MoonshotScore of 98 out of 100 and NVO (Novo Nordisk) has 91 (scores dated 2026-10-26). LLY scores 7 points higher. The MoonshotScore is a model rating, not a recommendation.

What is the latest recorded share price of LLY and NVO?

LLY last recorded $1,279.14 and NVO $39.13 (quotes dated 2026-10-26). These are the last provider quotes we hold, not streaming prices.

Which is larger by market capitalization, LLY or NVO?

LLY has a market capitalization of $1.20T and NVO $173.0B (quotes dated 2026-10-26). LLY is about 7.0 times the size of NVO by market value.

Explore More Research

Stock Expert AI provides data and analysis tools for educational purposes. This is not financial advice. Past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures.